Galecto, Inc. (GLTO)
Largest Insider Buys in Sector
GLTO Stock Price History Chart
GLTO Stock Performance
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Insider Activity of Galecto, Inc.
Over the last 12 months, insiders at Galecto, Inc. have bought $0 and sold $1.83M worth of Galecto, Inc. stock.
On average, over the past 5 years, insiders at Galecto, Inc. have bought $22.07M and sold $1.21M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $10,750 was made by Schambye Hans T. (Chief Executive Officer) on 2022‑03‑22.
List of Insider Buy and Sell Transactions, Galecto, Inc.
| 2023-08-15 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 822,680 3.5684% | $0.75 | $617,010 | -5.71% | |
| 2023-07-31 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 209,400 0.8023% | $3.00 | $628,200 | -79.08% | |
| 2023-07-25 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 39,200 0.1462% | $2.92 | $114,464 | -78.77% | |
| 2023-07-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 194,700 0.7339% | $2.40 | $467,280 | -73.66% | |
| 2023-04-17 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 12,429 0.0461% | $1.97 | $24,485 | -66.45% | |
| 2023-04-17 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,089 0.0485% | $1.97 | $25,785 | -66.45% | |
| 2023-04-14 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 39,355 0.1501% | $1.86 | $73,200 | -63.26% | |
| 2023-04-14 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 41,446 0.158% | $1.86 | $77,090 | -63.26% | |
| 2023-04-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,243 0.0519% | $1.82 | $24,102 | -61.41% | |
| 2023-04-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,946 0.0546% | $1.82 | $25,382 | -61.41% | |
| 2023-04-12 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 2,363 0.0093% | $1.81 | $4,277 | -60.96% | |
| 2023-04-11 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,946 0.0543% | $1.82 | $25,382 | -61.54% | |
| 2023-04-10 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 51,228 0.1984% | $1.79 | $91,698 | -61.11% | |
| 2023-04-06 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 9,665 0.0396% | $2.00 | $19,330 | -63.16% | |
| 2023-04-05 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 92,965 0.3672% | $2.18 | $202,664 | -67.44% | |
| 2022-03-22 | Schambye Hans T. | Chief Executive Officer | 5,000 0.0194% | $2.15 | $10,750 | -12.79% | ||
| 2022-03-22 | Lindmark Bertil | Chief Medical Officer | 14,604 0.057% | $2.16 | $31,545 | -12.79% | ||
| 2021-12-03 | Freve Jonathan | Chief Financial Officer | 4,000 0.0164% | $2.49 | $9,960 | -16.67% | ||
| 2021-12-03 | Winslow Garrett | General Counsel | 2,000 0.0082% | $2.48 | $4,960 | -16.67% | ||
| 2021-11-09 | Schambye Hans T. | Chief Executive Officer | 4,500 0.0178% | $3.50 | $15,750 | -40.86% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 10 percent owner | 97204 0.3585% | $0.49 | 1 | 15 | <0.0001% |
| Khuong Chau Quang | 2579657 9.5146% | $0.49 | 1 | 0 | <0.0001% | |
| Novo Holdings A/S | 10 percent owner | 2497791 9.2126% | $0.49 | 1 | 0 | <0.0001% |
| Christgau Stephan | director | 546136 2.0143% | $0.49 | 1 | 0 | <0.0001% |
| Schambye Hans T. | Chief Executive Officer | 52428 0.1934% | $0.49 | 3 | 0 | <0.0001% |
| Lindmark Bertil | Chief Medical Officer | 16604 0.0612% | $0.49 | 2 | 0 | <0.0001% |
| Freve Jonathan | Chief Financial Officer | 12000 0.0443% | $0.49 | 4 | 0 | <0.0001% |
| Winslow Garrett | General Counsel | 4000 0.0148% | $0.49 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Novo Holdings A/S | $1.95M | 9.21 | 2.5M | 0% | +$0 | 0.14 | |
| Renaissance Technologies | $452,000.00 | 2.13 | 578,983 | +42.27% | +$134,288.54 | <0.01 | |
| The Vanguard Group | $172,536.00 | 0.82 | 221,200 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $162,535.00 | 0.77 | 208,333 | 0% | +$0 | <0.0001 | |
| Citadel Advisors LLC | $72,931.00 | 0.35 | 93,501 | +29.09% | +$16,433.09 | <0.0001 | |
| Bridgeway Capital Management | $57,018.00 | 0.27 | 73,100 | -40.62% | -$39,000.00 | <0.01 | |
| BlackRock | $39,800.00 | 0.19 | 51,025 | -2.08% | -$843.19 | <0.0001 | |
| State Street | $35,027.00 | 0.17 | 44,906 | 0% | +$0 | <0.0001 | |
| Bank of America | $23,713.00 | 0.11 | 30,401 | 0% | +$0 | <0.0001 | |
| Jane Street Capital | $20,446.00 | 0.1 | 26,213 | New | +$20,446.00 | <0.0001 | |
| Summit Trail Advisors | $19,500.00 | 0.09 | 25,000 | New | +$19,500.00 | <0.01 | |
| Northern Trust | $16,030.00 | 0.08 | 20,551 | 0% | +$0 | <0.0001 | |
| Xtx Topco Ltd | $14,233.00 | 0.07 | 18,247 | New | +$14,233.00 | <0.01 | |
| Charles Schwab | $12,294.00 | 0.06 | 15,761 | 0% | +$0 | <0.0001 | |
| Millennium Management LLC | $10,922.00 | 0.05 | 14,002 | New | +$10,922.00 | <0.0001 | |
| Morgan Stanley | $5,461.00 | 0.03 | 7,001 | +700,000% | +$5,460.22 | <0.0001 | |
| JPMorgan Chase | $2,310.00 | 0.01 | 2,962 | +248.88% | +$1,647.88 | <0.0001 | |
| Spire Wealth Management | $1,560.00 | 0.01 | 2,000 | 0% | +$0 | <0.0001 | |
| Ica Group Wealth Management Llc | $585.00 | <0.01 | 750 | New | +$585.00 | <0.0001 | |
| Tower Research Capital | $374.00 | <0.01 | 479 | -93.9% | -$5,759.13 | <0.0001 | |
| Simplex Trading Llc | $0 | <0.01 | 547 | +592.4% | +$0 | <0.0001 | |
| Northwestern Mutual Wealth Management Co | $390.00 | <0.01 | 500 | New | +$390.00 | <0.0001 | |
| Wells Fargo | $121.00 | <0.01 | 155 | +1.97% | +$2.34 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 75 | -30.56% | -$0 | <0.0001 |